What it is
Celecoxib is the main representative of the selective COX-2 inhibitors, a class of NSAIDs designed to improve gastrointestinal tolerance. By mainly inhibiting COX-2 (responsible for inflammation) while sparing COX-1 (which protects the stomach), it causes fewer ulcers than non-selective NSAIDs.
This makes it suitable for long-term use or for patients at high gastrointestinal risk. However, it needs special care when there is cardiovascular risk.
Mechanism of action
Celecoxib acts selectively:
- Preferential inhibition of COX-2 (the inflammatory isoform), sparing COX-1
- Lower synthesis of pro-inflammatory prostaglandins without affecting production of the protective gastric mucus
- Less impact on platelet aggregation than non-selective NSAIDs
At the counter
When to recommend it
- Osteoarthritis, especially in patients at high gastrointestinal risk
- Rheumatoid arthritis in patients who need a long-term NSAID
- Ankylosing spondylitis
- Patients with a history of ulcer who need an NSAID, always on prescription
When not to
- Established cardiovascular disease (previous heart attack, stroke, heart failure)
- Uncontrolled high blood pressure
- Moderate to severe liver failure
- Allergy to sulphonamides (celecoxib has a sulphonamide structure)
Warnings
- Important Cardiovascular risk: it increases the risk of heart attack and stroke with long-term use, especially when there are pre-existing risk factors.
- Important Cross-allergy with sulphonamides: check for allergies before supplying it.
- Caution Better gastrointestinal tolerance than non-selective NSAIDs, but there is still a risk of ulcer. It is not absolutely 'safe'.
- Caution Fluid retention: monitor blood pressure and signs of cardiac decompensation.
Pharmacokinetics
- Absorption
- Slow oral absorption. Fatty meals delay the peak but slightly increase the amount absorbed. Peak plasma level at 2–3 hours.
- Distribution
- High plasma protein binding (97%). It distributes into joints and inflamed tissues. It crosses the placenta and is excreted in breast milk.
- Metabolism
- Hepatic metabolism via CYP2C9 and CYP3A4. It mainly produces an inactive metabolite.
- Elimination
- Renal elimination of metabolites. Long half-life (about 11 hours), allowing once- or twice-daily dosing.
Celecoxib vs ibuprofen
| Aspect | Celecoxib | Ibuprofen |
|---|---|---|
| COX-2 selectivity | Selective | Non-selective |
| Gastrointestinal risk | Lower | Higher |
| Cardiovascular risk | Increased with long-term use | Increased with long-term use |
| Analgesic potency | Moderate to high | Moderate to high |
| Ideal indication | Chronic inflammatory pain | Acute or subacute pain |
Choose celecoxib if the patient needs a long-term NSAID and has a high gastrointestinal risk. Ibuprofen is better for occasional, short use.
Self-assessment
Three questions. When you check your answers you will see the explanation for each one.
-
Celecoxib is selective for COX-2, which spares COX-1 in the stomach lining and reduces the risk of ulcer. There is still a risk, however, especially with predisposing factors. And it does carry cardiovascular risk.
-
With a history of ulcer, a selective COX-2 inhibitor has better gastric tolerance than a classic NSAID, and it is an option the doctor can consider —together with gastric protection and the patient's cardiovascular risk.
-
Celecoxib is an NSAID: combining it with another multiplies the gastric, kidney and cardiovascular risk without adding pain relief. Paracetamol is the option for occasional pain, and stopping a prescribed treatment is not a decision for the counter.
Training content. It does not replace the summary of product characteristics or clinical judgement.